WO2014191885A3 - Compositions and methods for the treatment of neuromuscular disorders - Google Patents
Compositions and methods for the treatment of neuromuscular disorders Download PDFInfo
- Publication number
- WO2014191885A3 WO2014191885A3 PCT/IB2014/061687 IB2014061687W WO2014191885A3 WO 2014191885 A3 WO2014191885 A3 WO 2014191885A3 IB 2014061687 W IB2014061687 W IB 2014061687W WO 2014191885 A3 WO2014191885 A3 WO 2014191885A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- treatment
- compositions
- disease
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
Abstract
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of neuromuscular disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of arthritis, congestive heart failure, Parkinson's disease, disuse atrophy, gyrate atrophy, McArdle's disease, Huntington's disease, mitochondrial diseases, muscular dystrophy, neuroprotection and depression.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2317CH2013 | 2013-05-27 | ||
IN2317/CHE/2013 | 2013-05-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014191885A2 WO2014191885A2 (en) | 2014-12-04 |
WO2014191885A3 true WO2014191885A3 (en) | 2015-04-02 |
Family
ID=51989477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/061687 WO2014191885A2 (en) | 2013-05-27 | 2014-05-24 | Compositions and methods for the treatment of neuromuscular disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014191885A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2622478A1 (en) * | 2007-02-20 | 2008-08-20 | Multi Formulations Ltd. | Creatine-fatty acids |
WO2010074591A1 (en) * | 2008-12-24 | 2010-07-01 | Закрытое Акционерное Общество "Beptekc" | Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action |
WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
-
2014
- 2014-05-24 WO PCT/IB2014/061687 patent/WO2014191885A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2622478A1 (en) * | 2007-02-20 | 2008-08-20 | Multi Formulations Ltd. | Creatine-fatty acids |
WO2010074591A1 (en) * | 2008-12-24 | 2010-07-01 | Закрытое Акционерное Общество "Beptekc" | Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action |
WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
Also Published As
Publication number | Publication date |
---|---|
WO2014191885A2 (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013075A (en) | Oxysterols and methods of use thereof. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2017011951A (en) | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use. | |
PH12015502524A1 (en) | New somatostatin receptor subtype 4 (sstr4) agonists | |
WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
WO2013175376A3 (en) | Compositions and methods for the treatment of local pain | |
PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
WO2016046680A3 (en) | Compositions and methods for the treatment of liver metabolic diseases | |
WO2014068463A3 (en) | Compositions and methods for the treatment of inflammation and metabolic disorders | |
WO2014087307A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
WO2008145524A3 (en) | 4,4-disubstituted piperidine derivatives | |
WO2013175359A3 (en) | Compositions and methods for the treatment of multiple sclerosis | |
WO2014091384A3 (en) | Compositions and methods for the treatment of mucositis | |
WO2014106804A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
WO2014195850A3 (en) | Compositions and methods for the treatment of neurologic diseases and neurological disorders | |
WO2014087323A3 (en) | Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases | |
WO2014097137A3 (en) | Compositions and methods for the treatment of seizures and neurologic diseases | |
WO2013167989A3 (en) | Compositions and methods for the treatment of neurological disorders | |
WO2014191885A3 (en) | Compositions and methods for the treatment of neuromuscular disorders | |
MX2019005568A (en) | Compositions and methods for the treatment of gastrointestinal polyps. | |
WO2015028976A3 (en) | Compounds and methods for the treatment of inflammatory diseases | |
WO2014122621A3 (en) | Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases | |
WO2014068459A3 (en) | Compositions and methods for the treatment of pain and neurological diseases | |
WO2014006528A3 (en) | Compositions and methods for the treatment of neurological degenerative disorders | |
WO2014195810A3 (en) | Compositions and methods for the treatment of diabetes and pre-diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14803340 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14803340 Country of ref document: EP Kind code of ref document: A2 |